HATTRICK-OCT: biodegradable polymer struts coverage versus permanent

Late endothelialization of first generation pharmacological stents may predispose thrombosis. Both the drug and the polymer of the platform may affect the rate at which this occurs. This is a prospective, multicenter study which randomized 44 patients with acute coronary syndrome to receive sirolimus-eluting stent with bio-absorbable polymer versus zotarolimus-eluting stent with permanent polymer. The coating of the struts was assessed by OCT and the vasodilator response using CFR. 

There were no differences in clinical characteristics of patients but there was a significant difference in favor of the stent with bio-absorbable polymer in the number of struts not covered by OCT, (189/3.9% versus 495/8.9%, p <0.001), as well as in the amount of badly placed struts, (292/5.3 126/2.6% versus %, p <0.001). 

Conclusion: The sirolimus-eluting stent with bio-absorbable polymer showed better covered struts by endothelium after three months of angioplasty compared with the zotarolimus eluting stent with permanent polymer.

tuomas_kiviniemi_europcr
Tuomas Kiviniemi
2013-05-22

Original title: Early vascular healing of hybrid sirolimus-eluting stents with bioabsorbable polymer versus zotarolimus-eluting stents with durable polymer – HATTRICK-OCT Trial. 

More articles by this author

REPRISE II: results obtained with the new valve according to VARC criteria

The objective was to evaluate the safety and efficacy of the Lotus Valve System to treat patients with severe aortic stenosis and high surgical...

DEFLECT I: cerebral protection device in TAVI

Strokes after TAVI occur in between 3.8 and 6.7% of the cases, with new MRI lesions being almost the rule. The TriGuard EDD device...

DISCOVER: new low profile valve with little post-implant regurgitation

The objective of the study was to assess events after 30 days with the DirectFLOW Medical Valve device in patients with severe aortic stenosis...

JUPITER: transapical TAVI device

We evaluated 88 consecutive patients (at this phase) with severe aortic stenosis who received the second-generation device for transapical access. Survival at thirty days...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...